Grace Therapeutics, Inc.
GRCE
$3.02
$0.072.37%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -5.63% | 13.66% | 20.33% | -37.50% | -10.86% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.72% | 130.93% | 67.16% | -22.90% | -28.32% |
| Operating Income | -21.72% | -130.93% | -67.16% | 22.90% | 28.32% |
| Income Before Tax | -83.15% | -15.19% | 22.52% | 89.32% | 37.57% |
| Income Tax Expenses | -190.87% | -91.03% | -150.52% | 89.98% | 24.09% |
| Earnings from Continuing Operations | -73.78% | -4.86% | 34.95% | 89.12% | 38.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -73.78% | -4.86% | 34.95% | 89.12% | 38.52% |
| EBIT | -21.72% | -130.93% | -67.16% | 22.90% | 28.32% |
| EBITDA | -21.70% | -131.05% | -67.52% | 22.78% | 28.17% |
| EPS Basic | -73.77% | 31.17% | 55.74% | 92.90% | 60.27% |
| Normalized Basic EPS | -83.14% | 24.40% | 19.57% | 35.53% | 59.65% |
| EPS Diluted | -73.77% | 31.17% | 55.65% | 92.90% | 60.27% |
| Normalized Diluted EPS | -83.14% | 24.40% | 19.57% | 35.53% | 59.65% |
| Average Basic Shares Outstanding | 0.00% | 52.35% | 46.98% | 53.37% | 54.75% |
| Average Diluted Shares Outstanding | 0.00% | 52.35% | 46.98% | 53.37% | 54.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |